These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 27712768

  • 1. Lipid Mediators in Aspirin-Exacerbated Respiratory Disease.
    Parker AR, Ayars AG, Altman MC, Henderson WR.
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):749-763. PubMed ID: 27712768
    [Abstract] [Full Text] [Related]

  • 2. Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease.
    Steinke JW, Payne SC, Borish L.
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):719-734. PubMed ID: 27712766
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of Benefit with Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease.
    Hill J, Burnett T, Katial R.
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):735-747. PubMed ID: 27712767
    [Abstract] [Full Text] [Related]

  • 4. Pathogenesis of aspirin-exacerbated respiratory disease and reactions.
    Laidlaw TM, Boyce JA.
    Immunol Allergy Clin North Am; 2013 May; 33(2):195-210. PubMed ID: 23639708
    [Abstract] [Full Text] [Related]

  • 5. Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory Disease.
    Cahill KN, Laidlaw TM.
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):681-691. PubMed ID: 27712763
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Aspirin exacerbated respiratory disease: Current topics and trends.
    Rodríguez-Jiménez JC, Moreno-Paz FJ, Terán LM, Guaní-Guerra E.
    Respir Med; 2018 Feb; 135():62-75. PubMed ID: 29414455
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease.
    Dahlin A, Weiss ST.
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):765-789. PubMed ID: 27712769
    [Abstract] [Full Text] [Related]

  • 13. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.
    White AA, Stevenson DD, Simon RA.
    Ann Allergy Asthma Immunol; 2005 Oct; 95(4):330-5. PubMed ID: 16279562
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.
    Stevens WW, Schleimer RP.
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):669-680. PubMed ID: 27712762
    [Abstract] [Full Text] [Related]

  • 20. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.
    Mastalerz L, Celejewska-Wójcik N, Wójcik K, Gielicz A, Januszek R, Cholewa A, Stręk P, Sanak M.
    Allergy; 2014 Nov; 69(11):1550-9. PubMed ID: 25123806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.